Vertex keeps cystic fibrosis drug out of developing countries, NY Times reports

Vertex Pharmaceuticals is not making its new cystic firbosis drug, Trikafta, available virtually anywhere in the developing world, Stephanie Nolen and Rebecca Robbins of The New York Times reports. The company is not trying to sell it or allow local companies to make it nor it is allowing potential generic competitors by seeking patents in various countries. Trikafta is the most powerful and widely used of Vertex’s cystic fibrosis medications. A group of patients and their families in four countries have recently initiated legal and regulatory steps to try to force their governments to override the intellectual property protections in place for Vertex to allow a low-cost generic version of Trikafta to be made locally or imported. Reference Link